NASDAQ:CRVL

CorVel Competitors

$106.94
+1.07 (+1.01 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$105.44
Now: $106.94
$107.26
50-Day Range
$101.50
MA: $104.77
$110.46
52-Week Range
$44.67
Now: $106.94
$111.42
Volume25,454 shs
Average Volume43,655 shs
Market Capitalization$1.91 billion
P/E Ratio47.53
Dividend YieldN/A
Beta0.87

Competitors

CorVel (NASDAQ:CRVL) Vs. LH, DGX, DVA, AMED, CHE, and RCM

Should you be buying CRVL stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to CorVel, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), and R1 RCM (RCM).

Laboratory Co. of America (NYSE:LH) and CorVel (NASDAQ:CRVL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Valuation and Earnings

This table compares Laboratory Co. of America and CorVel's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion2.15$823.80 million$11.3222.50
CorVel$592.22 million3.23$47.38 millionN/AN/A

Laboratory Co. of America has higher revenue and earnings than CorVel.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Laboratory Co. of America and CorVel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011402.93
CorVel0000N/A

Laboratory Co. of America presently has a consensus price target of $240.1429, suggesting a potential downside of 5.73%. Given Laboratory Co. of America's higher possible upside, research analysts plainly believe Laboratory Co. of America is more favorable than CorVel.

Profitability

This table compares Laboratory Co. of America and CorVel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America6.79%21.05%8.83%
CorVel7.36%21.07%9.68%

Insider & Institutional Ownership

89.3% of Laboratory Co. of America shares are held by institutional investors. Comparatively, 47.9% of CorVel shares are held by institutional investors. 0.7% of Laboratory Co. of America shares are held by company insiders. Comparatively, 50.4% of CorVel shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Laboratory Co. of America has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, CorVel has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Quest Diagnostics (NYSE:DGX) and CorVel (NASDAQ:CRVL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 47.9% of CorVel shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by insiders. Comparatively, 50.4% of CorVel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Quest Diagnostics and CorVel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
CorVel7.36%21.07%9.68%

Analyst Recommendations

This is a summary of current ratings and target prices for Quest Diagnostics and CorVel, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics010602.38
CorVel0000N/A

Quest Diagnostics currently has a consensus price target of $128.8750, suggesting a potential upside of 1.72%. Given Quest Diagnostics' higher possible upside, analysts plainly believe Quest Diagnostics is more favorable than CorVel.

Risk & Volatility

Quest Diagnostics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, CorVel has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares Quest Diagnostics and CorVel's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.19$858 million$6.5619.31
CorVel$592.22 million3.23$47.38 millionN/AN/A

Quest Diagnostics has higher revenue and earnings than CorVel.

Summary

Quest Diagnostics beats CorVel on 7 of the 12 factors compared between the two stocks.

CorVel (NASDAQ:CRVL) and DaVita (NYSE:DVA) are both business services companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares CorVel and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CorVel7.36%21.07%9.68%
DaVita7.32%43.99%5.27%

Valuation and Earnings

This table compares CorVel and DaVita's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CorVel$592.22 million3.23$47.38 millionN/AN/A
DaVita$11.39 billion1.05$810.98 million$5.4020.19

DaVita has higher revenue and earnings than CorVel.

Insider & Institutional Ownership

47.9% of CorVel shares are owned by institutional investors. Comparatively, 91.7% of DaVita shares are owned by institutional investors. 50.4% of CorVel shares are owned by company insiders. Comparatively, 1.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CorVel and DaVita, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CorVel0000N/A
DaVita13102.00

DaVita has a consensus price target of $114.60, suggesting a potential upside of 5.14%. Given DaVita's higher probable upside, analysts plainly believe DaVita is more favorable than CorVel.

Risk and Volatility

CorVel has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.

Summary

DaVita beats CorVel on 7 of the 12 factors compared between the two stocks.

CorVel (NASDAQ:CRVL) and Amedisys (NASDAQ:AMED) are both business services companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares CorVel and Amedisys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CorVel7.36%21.07%9.68%
Amedisys8.22%26.41%12.43%

Valuation and Earnings

This table compares CorVel and Amedisys' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CorVel$592.22 million3.23$47.38 millionN/AN/A
Amedisys$1.96 billion4.76$126.83 million$4.4064.34

Amedisys has higher revenue and earnings than CorVel.

Insider & Institutional Ownership

47.9% of CorVel shares are owned by institutional investors. Comparatively, 85.9% of Amedisys shares are owned by institutional investors. 50.4% of CorVel shares are owned by company insiders. Comparatively, 2.8% of Amedisys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

CorVel has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CorVel and Amedisys, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CorVel0000N/A
Amedisys03902.75

Amedisys has a consensus price target of $274.4615, suggesting a potential downside of 3.05%. Given Amedisys' higher probable upside, analysts plainly believe Amedisys is more favorable than CorVel.

Summary

Amedisys beats CorVel on 10 of the 12 factors compared between the two stocks.

CorVel (NASDAQ:CRVL) and Chemed (NYSE:CHE) are both business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.

Insider and Institutional Ownership

47.9% of CorVel shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 50.4% of CorVel shares are owned by company insiders. Comparatively, 4.0% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for CorVel and Chemed, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CorVel0000N/A
Chemed00103.00

Chemed has a consensus target price of $580.00, suggesting a potential upside of 24.63%. Given Chemed's higher probable upside, analysts clearly believe Chemed is more favorable than CorVel.

Profitability

This table compares CorVel and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CorVel7.36%21.07%9.68%
Chemed13.11%38.13%21.70%

Valuation & Earnings

This table compares CorVel and Chemed's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CorVel$592.22 million3.23$47.38 millionN/AN/A
Chemed$1.94 billion3.85$219.92 million$13.9533.36

Chemed has higher revenue and earnings than CorVel.

Volatility and Risk

CorVel has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats CorVel on 9 of the 12 factors compared between the two stocks.

R1 RCM (NASDAQ:RCM) and CorVel (NASDAQ:CRVL) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Earnings and Valuation

This table compares R1 RCM and CorVel's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
R1 RCM$1.19 billion5.60$12 million($0.08)-317.75
CorVel$592.22 million3.23$47.38 millionN/AN/A

CorVel has lower revenue, but higher earnings than R1 RCM.

Insider & Institutional Ownership

81.2% of R1 RCM shares are held by institutional investors. Comparatively, 47.9% of CorVel shares are held by institutional investors. 59.4% of R1 RCM shares are held by insiders. Comparatively, 50.4% of CorVel shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares R1 RCM and CorVel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
R1 RCM3.69%117.07%4.39%
CorVel7.36%21.07%9.68%

Risk & Volatility

R1 RCM has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, CorVel has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for R1 RCM and CorVel, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
R1 RCM00503.00
CorVel0000N/A

R1 RCM presently has a consensus target price of $28.60, suggesting a potential upside of 12.51%. Given R1 RCM's higher probable upside, equities research analysts plainly believe R1 RCM is more favorable than CorVel.

Summary

R1 RCM beats CorVel on 9 of the 12 factors compared between the two stocks.


CorVel Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.4$254.75+1.1%$24.87 billion$11.55 billion29.66
Quest Diagnostics logo
DGX
Quest Diagnostics
1.9$126.69+0.0%$16.91 billion$7.73 billion15.66Ex-Dividend
DaVita logo
DVA
DaVita
1.7$109.00+2.0%$11.92 billion$11.39 billion16.34
Amedisys logo
AMED
Amedisys
1.2$283.09+3.4%$9.30 billion$1.96 billion56.73News Coverage
Gap Up
Chemed logo
CHE
Chemed
2.2$465.37+0.8%$7.46 billion$1.94 billion28.22
R1 RCM logo
RCM
R1 RCM
1.8$25.42+1.1%$6.64 billion$1.19 billion282.48Insider Selling
LHC Group logo
LHCG
LHC Group
1.7$203.84+1.6%$6.44 billion$2.08 billion61.96
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.3$75.86+1.2%$3.58 billion$2.22 billion40.57Analyst Report
News Coverage
MEDNAX logo
MD
MEDNAX
1.4$25.75+0.5%$2.22 billion$3.51 billion-2.98Unusual Options Activity
News Coverage
The Providence Service logo
PRSC
The Providence Service
0.8$141.00+1.4%$2.00 billion$1.51 billion-2,349.61
Tivity Health logo
TVTY
Tivity Health
1.0$23.56+0.5%$1.16 billion$1.13 billion-2.13
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.1$12.76+1.1%$478.67 million$822.22 million-24.54
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.7$8.30+6.9%$34.06 million$24.08 million-0.98Analyst Report
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.